Literature DB >> 22561128

Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats.

Martina L Mustroph1, Michael A King, Ronald L Klein, Julio J Ramirez.   

Abstract

Tauopathy in the hippocampus is one of the earliest cardinal features of Alzheimer's disease (AD), a condition characterized by progressive memory impairments. In fact, density of tau neurofibrillary tangles (NFTs) in the hippocampus strongly correlates with severity of cognitive impairments in AD. In the present study, we employed a somatic cell gene transfer technique to create a rodent model of tauopathy by injecting a recombinant adeno-associated viral vector with a mutated human tau gene (P301L) into the hippocampus of adult rats. The P301L mutation is causal for frontotemporal dementia with parkinsonism-17 (FTDP-17), but it has been used for studying memory effects characteristic of AD in transgenic mice. To ascertain if P301L-induced mnemonic deficits are persistent, animals were tested for 6 months. It was hypothesized that adult-onset, spatially restricted tau expression in the hippocampus would produce progressive spatial working memory deficits on a learned alternation task. Rats injected with the tau vector exhibited persistent impairments on the hippocampal-dependent task beginning at about 6 weeks post-transduction compared to rats injected with a green fluorescent protein vector. Histological analysis of brains for expression of human tau revealed hyperphosphorylated human tau and NFTs in the hippocampus in experimental animals only. Thus, adult-onset, vector-induced tauopathy spatially restricted to the hippocampus progressively impaired spatial working memory in rats. We conclude that the model faithfully reproduces histological and behavioral findings characteristic of dementing tauopathies. The rapid onset of sustained memory impairment establishes a preclinical model particularly suited to the development of potential tauopathy therapeutics.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561128      PMCID: PMC3378764          DOI: 10.1016/j.bbr.2012.04.034

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  67 in total

Review 1.  Separate mechanisms for short- and long-term memory.

Authors:  I Izquierdo; J H Medina; M R Vianna; L A Izquierdo; D M Barros
Journal:  Behav Brain Res       Date:  1999-08       Impact factor: 3.332

2.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

3.  Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Authors:  Martin Ramsden; Linda Kotilinek; Colleen Forster; Jennifer Paulson; Eileen McGowan; Karen SantaCruz; Aaron Guimaraes; Mei Yue; Jada Lewis; George Carlson; Michael Hutton; Karen H Ashe
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

Review 4.  Copernicus revisited: amyloid beta in Alzheimer's disease.

Authors:  J Joseph; B Shukitt-Hale; N A Denisova; A Martin; G Perry; M A Smith
Journal:  Neurobiol Aging       Date:  2001 Jan-Feb       Impact factor: 4.673

5.  Differentiating the roles of the hippocampal complex and the neocortex in long-term memory storage: evidence from the study of semantic dementia and Alzheimer's disease.

Authors:  Kim S Graham; John R Hodges
Journal:  Neuropsychology       Date:  1997-01       Impact factor: 3.295

6.  Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation.

Authors:  Tetsuro Murakami; Erwan Paitel; Takeshi Kawarabayashi; Masaki Ikeda; M Azhar Chishti; Christopher Janus; Etsuro Matsubara; Atsushi Sasaki; Toshitaka Kawarai; Amie L Phinney; Yasuo Harigaya; Patrick Horne; Nobuaki Egashira; Kenichi Mishima; Amanda Hanna; Jing Yang; Katsunori Iwasaki; Mitsuo Takahashi; Michihiro Fujiwara; Koichi Ishiguro; Catherine Bergeron; George A Carlson; Koji Abe; David Westaway; Peter St George-Hyslop; Mikio Shoji
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

7.  Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats.

Authors:  Miroslava Hrnkova; Norbert Zilka; Zuzana Minichova; Peter Koson; Michal Novak
Journal:  Brain Res       Date:  2006-12-13       Impact factor: 3.252

8.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

9.  New expression of myelomonocytic antigens by microglia and perivascular cells following lethal motor neuron injury.

Authors:  M B Graeber; W J Streit; R Kiefer; S W Schoen; G W Kreutzberg
Journal:  J Neuroimmunol       Date:  1990-05       Impact factor: 3.478

10.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

View more
  8 in total

Review 1.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

2.  Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.

Authors:  Raphaëlle Caillierez; Séverine Bégard; Katia Lécolle; Vincent Deramecourt; Nadège Zommer; Simon Dujardin; Anne Loyens; Noëlle Dufour; Gwennaëlle Aurégan; Joris Winderickx; Philippe Hantraye; Nicole Déglon; Luc Buée; Morvane Colin
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

3.  A dramatic increase of C1q protein in the CNS during normal aging.

Authors:  Alexander H Stephan; Daniel V Madison; José María Mateos; Deborah A Fraser; Emilie A Lovelett; Laurence Coutellier; Leo Kim; Hui-Hsin Tsai; Eric J Huang; David H Rowitch; Dominic S Berns; Andrea J Tenner; Mehrdad Shamloo; Ben A Barres
Journal:  J Neurosci       Date:  2013-08-14       Impact factor: 6.167

4.  Expression of P301L-hTau in mouse MEC induces hippocampus-dependent memory deficit.

Authors:  Xinghua Liu; Kuan Zeng; Mengzhu Li; Qun Wang; Rong Liu; Bin Zhang; Jian-Zhi Wang; Xiji Shu; Xiaochuan Wang
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

5.  Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment.

Authors:  Robert John Hatch; Yan Wei; Di Xia; Jürgen Götz
Journal:  Acta Neuropathol       Date:  2017-01-16       Impact factor: 17.088

6.  Codonopsis pilosula Polysaccharide Attenuates Tau Hyperphosphorylation and Cognitive Impairments in hTau Infected Mice.

Authors:  Qing Zhang; Yiyuan Xia; Hongbin Luo; Sheng Huang; Yongjun Wang; Yangping Shentu; Yacoubou Abdoul Razak Mahaman; Fang Huang; Dan Ke; Qun Wang; Rong Liu; Jian-Zhi Wang; Bin Zhang; Xiaochuan Wang
Journal:  Front Mol Neurosci       Date:  2018-11-27       Impact factor: 5.639

7.  Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein.

Authors:  Alexander J Moszczynski; Madeline Harvey; Niveen Fulcher; Cleusa de Oliveira; Patrick McCunn; Neil Donison; Robert Bartha; Susanne Schmid; Michael J Strong; Kathryn Volkening
Journal:  Acta Neuropathol Commun       Date:  2019-11-08       Impact factor: 7.801

Review 8.  Alterations in Tau Metabolism in ALS and ALS-FTSD.

Authors:  Michael J Strong; Neil S Donison; Kathryn Volkening
Journal:  Front Neurol       Date:  2020-11-23       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.